Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amphastar Pharma (NQ: AMPH )

37.75 +0.99 (+2.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 8, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 453,373
Open 36.53
Bid (Size) 36.50 (1)
Ask (Size) 38.10 (9)
Prev. Close 36.76
Today's Range 36.53 - 38.20
52wk Range 17.56 - 44.46
Shares Outstanding 48,829,793
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Amphastar Pharmaceuticals: Q2 Earnings Insights
  Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Amphastar, Syndax Top Second-Quarter Estimates, But Runaway Biotechs At A Standstill
Amphastar came in well above forecasts, while Syndax had fewer than expected losses. 
Via Investor's Business Daily

Performance

YTD
+64.26%
+64.26%
1 Month
+4.54%
+4.54%
3 Month
+18.86%
+18.86%
6 Month
+43.70%
+43.70%
1 Year
+88.00%
+88.00%

More News

Read More
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
Via ACCESSWIRE
Kura Oncology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
Via Benzinga
Keep Amphastar Pharmaceuticals Stock On Your Watch List Ahead Of Earnings
Via Investor's Business Daily
Amphastar Receives FDA Approval for Vasopressin
Via ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
From Amphastar Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Crispr Therapeutics Stock Shows Rising Price Performance With Jump To 94 RS Rating
Via Investor's Business Daily
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
Via Investor's Business Daily
Prometheus Biosciences Stock Shows Rising Relative Strength
Via Investor's Business Daily
Merus Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
Via Investor's Business Daily
Vir Biotechnology Stock Joins Rank Of Stocks With RS Ratings Over 90
Via Investor's Business Daily
Uniqure Stock Sees Healthy Price Gain, Ranks Among Top 8%
Via Investor's Business Daily
Global Blood Therapeutic Stock Sees Relative Strength Rating Rise To 91
Via Investor's Business Daily
Amphastar Pharmaceuticals Stock Scores Composite Rating Climb To 96
Via Investor's Business Daily
Kura Oncology Stock Scores Rising Relative Strength
Via Investor's Business Daily
Syndax Pharmaceuticals Stock Sees RS Rating Rise To 92
Via Investor's Business Daily
Amylyx Pharmaceuticals Stock Clears Key Benchmark, Hitting 90-Plus RS Rating
Via Investor's Business Daily
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade
Via Investor's Business Daily
69 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
36 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.